| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.3 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | 16-beta-bromoandrosterone | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |